TY - JOUR
T1 - Dragon method for finding novel tyrosinase inhibitors
T2 - Biosilico identification and experimental in vitro assays
AU - Casañola-Martín, Gerardo M.
AU - Marrero-Ponce, Yovani
AU - Khan, Mahmud Tareq Hassan
AU - Ather, Arjumand
AU - Khan, Khalid M.
AU - Torrens, Francisco
AU - Rotondo, Richard
N1 - Funding Information:
One of the authors (Y.M.-P.) thanks the program ‘Estades Temporals per a Investigadors Convidats’ for a fellowship to work at Valencia University (2006–2007). Y.M.-P. also thanks the Generalitat Valenciana, (Spain) for partial financial support as well as support from Spanish MEC (Project Reference: SAF2006-04698). M.T.H.K. is the recipient of a grant from MCBN-UNESCO (grant no. 1056), and fellowships from CIB (Italy) and Associasione Veneta per la Lotta alla Talassemia (AVTL, Italy). F.T. acknowledges financial support from the Spanish MEC DGI (Project No. CTQ2004-07768-C02-01/BQU) and Generalitat Valenciana (DGEUI INF01-051 and INFRA03-047, and OCYT GRUPOS03-173).
PY - 2007/11
Y1 - 2007/11
N2 - QSAR (quantitative structure-activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active data set was processed by k-means cluster analysis in order to design training and prediction series. Seven LDA-based QSAR models were obtained. The discriminant functions applied showed a globally good classification of 99.79% for the best model Class = - 96.067 + 1.988 × 102 X0Av + 91.907 BIC3 + 6.853 CIC1 in the training set. External validation processes to assess the robustness and predictive power of the obtained model were carried out. This external prediction set had an accuracy of 99.44%. After that, the developed models were used in ligand-based virtual screening of tyrosinase inhibitors from the literature and never considered in either training or predicting series. In this case, all screened chemicals were correctly classified by the LDA-based QSAR models. As a final point, these fitted models were used in the screening of new bipiperidine series as new tyrosinase inhibitors. These methods are an adequate alternative to the process of selection/identification of new bioactive compounds. The biosilico assays and in vitro results of inhibitory activity on mushroom tyrosinase showed good correspondence. It is important to stand out that compound BP4 (IC50 = 1.72 μM) showed higher activity in the inhibition against the enzyme than reference compound kojic acid (IC50 = 16.67 μM) and l-mimosine (IC50 = 3.68 μM). These results support the role of biosilico algorithm for the identification of new tyrosinase inhibitor compounds.
AB - QSAR (quantitative structure-activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active data set was processed by k-means cluster analysis in order to design training and prediction series. Seven LDA-based QSAR models were obtained. The discriminant functions applied showed a globally good classification of 99.79% for the best model Class = - 96.067 + 1.988 × 102 X0Av + 91.907 BIC3 + 6.853 CIC1 in the training set. External validation processes to assess the robustness and predictive power of the obtained model were carried out. This external prediction set had an accuracy of 99.44%. After that, the developed models were used in ligand-based virtual screening of tyrosinase inhibitors from the literature and never considered in either training or predicting series. In this case, all screened chemicals were correctly classified by the LDA-based QSAR models. As a final point, these fitted models were used in the screening of new bipiperidine series as new tyrosinase inhibitors. These methods are an adequate alternative to the process of selection/identification of new bioactive compounds. The biosilico assays and in vitro results of inhibitory activity on mushroom tyrosinase showed good correspondence. It is important to stand out that compound BP4 (IC50 = 1.72 μM) showed higher activity in the inhibition against the enzyme than reference compound kojic acid (IC50 = 16.67 μM) and l-mimosine (IC50 = 3.68 μM). These results support the role of biosilico algorithm for the identification of new tyrosinase inhibitor compounds.
KW - Bipiperidine series
KW - Dragon descriptor
KW - LDA-based QSAR model
KW - Tyrosinase inhibitor
KW - Virtual screening
UR - http://www.scopus.com/inward/record.url?scp=36348979773&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2007.01.026
DO - 10.1016/j.ejmech.2007.01.026
M3 - Artículo
C2 - 17637486
AN - SCOPUS:36348979773
SN - 0223-5234
VL - 42
SP - 1370
EP - 1381
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
IS - 11-12
ER -